147 related articles for article (PubMed ID: 6214446)
21. Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses.
Kimura M; Konno T; Miyamoto Y; Kojima Y; Maeda H
Anticancer Res; 1998; 18(4A):2547-50. PubMed ID: 9703908
[TBL] [Abstract][Full Text] [Related]
22. [SMANCS/lipiodol].
Maeda H
Gan To Kagaku Ryoho; 1994 May; 21(6):907-13. PubMed ID: 8185354
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of orally administered SMANCS, a polymer-conjugated protein drug, in mice bearing various murine tumors.
Schmitt DA; Kisanuki K; Kimura S; Oka K; Pollard RB; Maeda H; Suzuki F
Anticancer Res; 1992; 12(6B):2219-24. PubMed ID: 1295469
[TBL] [Abstract][Full Text] [Related]
24. [Recent advances in research on SMANCS].
Maeda H
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():1-9. PubMed ID: 9512680
[TBL] [Abstract][Full Text] [Related]
25. [Clinical experience of treatment of liver metastasis of renal cell carcinoma treated with SMANCS/Lipiodol therapy].
Umeda S; Ito K; Takahashi E; Kimura F; Sumitomo M; Kaji T; Hayakawa M; Asano T
Hinyokika Kiyo; 2010 Oct; 56(10):543-9. PubMed ID: 21063157
[TBL] [Abstract][Full Text] [Related]
26. [Antitumor activities of oily suspended YM881 (SMANCS) against VX2 carcinoma].
Kimura M; Konno T; Ohtsuka N; Mizumachi R; Oda T
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2183-8. PubMed ID: 2544148
[TBL] [Abstract][Full Text] [Related]
27. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium.
Maki S; Konno T; Maeda H
Cancer; 1985 Aug; 56(4):751-7. PubMed ID: 3160453
[TBL] [Abstract][Full Text] [Related]
28. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure.
Li CJ; Miyamoto Y; Kojima Y; Maeda H
Br J Cancer; 1993 May; 67(5):975-80. PubMed ID: 8494731
[TBL] [Abstract][Full Text] [Related]
29. [Intra-arterial injection of an oily antineoplastic agent in hepatic cancer].
Konno T; Tashiro S; Maeda H; Iwai K; Ogata K; Mochinaga M; Uemura K; Ishimaru S; Miyauchi Y; Yokoyama I
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):351-7. PubMed ID: 6309086
[TBL] [Abstract][Full Text] [Related]
30. Changes in the microvascular architecture of colorectal liver metastases following the administration of SMANCS/lipiodol.
Kuruppu D; Christophi C; Maeda H; O'Brien PE
J Surg Res; 2002 Mar; 103(1):47-54. PubMed ID: 11855917
[TBL] [Abstract][Full Text] [Related]
31. Antitumor mechanisms of zinostatin stimalamer (YM881).
Tanaka S; Yamamoto M; Numasaki Y
Res Commun Mol Pathol Pharmacol; 1996 May; 92(2):165-76. PubMed ID: 8774070
[TBL] [Abstract][Full Text] [Related]
32. [Subsegmental transcatheter hepatic arterial embolization under balloon occlusion of the corresponding hepatic vein with SMANCS].
Shibata H; Sogabe M; Tsutsui A; Yokoi T; Morimoto M; Fukuda T; Hayashi S; Muguruma N; Ohkita Y; Okahisa T; Okamura S; Ito S
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():133-40. PubMed ID: 9512701
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulating activities of orally administered SMANCS, a polymer-conjugated derivative of the proteinaceous antibiotic neocarzinostatin, in an oily formulation.
Suzuki F; Matsumoto K; Schmitt DA; Pollard RB; Maeda H
Int J Immunopharmacol; 1993 Feb; 15(2):175-83. PubMed ID: 7682198
[TBL] [Abstract][Full Text] [Related]
34. [Antitumor effects of a new antitumor agent, zinostatin stimalamer (YM881)--effects on experimental tumors in vitro and in vivo].
Numasaki Y; Takahashi K; Masuda E; Nohara C; Maeda H
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2289-94. PubMed ID: 1834021
[TBL] [Abstract][Full Text] [Related]
35. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties.
Maeda H; Ueda M; Morinaga T; Matsumoto T
J Med Chem; 1985 Apr; 28(4):455-61. PubMed ID: 3156994
[TBL] [Abstract][Full Text] [Related]
36. [SMANCS/TAE for hepatocellular carcinoma: comparison with SMANCS/TAI].
Shimizu T; Endou H
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():80-3. PubMed ID: 9512693
[TBL] [Abstract][Full Text] [Related]
37. Antiproliferative effect of YM881 (SMANCS) on glioma cells in vitro.
Kuratsu J; Takaki S; Kochi M; Mihara Y; Ushio Y
Anticancer Res; 1991; 11(6):1957-61. PubMed ID: 1837980
[TBL] [Abstract][Full Text] [Related]
38. [Arterial administration of high molecular weight antitumor agent, SMANCS dissolved in ethiodol for various malignant solid tumors].
Konno T; Iwai K; Maki S; Uchida M; Ogata K; Tashiro S; Miyauchi Y; Yokoyama I; Maeda H
Nihon Gan Chiryo Gakkai Shi; 1983 Oct; 18(7):1845-51. PubMed ID: 6323597
[No Abstract] [Full Text] [Related]
39. [Effect of YM 881 (SMANCS) in rats bearing intracerebrally implanted 9L glioma].
Kuratsu J; Takaki S; Mihara Y; Kochi M; Ushio Y
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1713-4. PubMed ID: 1831341
[No Abstract] [Full Text] [Related]
40. [Combination of transcatheter arterial infusion of SMANCS and embolization (SMANCS-TAE) for hepatocellular carcinoma--second report].
Hirashima N; Itazu I; Nukaya H; Kimura H; Hasegawa I; Yoshimizu T; Nemoto S; Sakakibara K
Gan To Kagaku Ryoho; 1998 May; 25(6):873-9. PubMed ID: 9617326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
